Research calls for greater investment in Alzheimer’s clinical trials
Despite some challenges, for the Alzheimer’s drug development pipeline, 2024 is a “learning year”, an expert on the disease says.
List view / Grid view
Despite some challenges, for the Alzheimer’s drug development pipeline, 2024 is a “learning year”, an expert on the disease says.
In this Drug Targets In-Depth Focus: GPCR allosteric modulation: new opportunities and challenges for drug discovery; Chloride channels and cardiac arrhythmia: novel therapeutic targets?